PMID- 19301157
OWN - NLM
STAT- MEDLINE
DCOM- 20110112
LR  - 20211203
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 27
IP  - 2
DP  - 2010 Jun
TI  - The mTOR pathway is associated with the poor prognosis of human hepatocellular 
      carcinoma.
PG  - 255-61
LID - 10.1007/s12032-009-9201-4 [doi]
AB  - OBJECTIVE: The mammalian target of rapamycin (mTOR) pathway, an important 
      regulator of multiple cellular functions including proliferation, 
      differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. 
      It has achieved considerable importance. This study was conducted to determine 
      the status of the mTOR pathway in human hepatocellular carcinoma (HCC) and to 
      investigate its relationship with the prognosis of HCC. METHODS: PTEN, pAkt, p27, 
      and pS6 expression in cryo-sections gathered from 528 cases with HCC by the 
      method of immunohistochemistry. Kaplan-Meier survival and Cox regression analyses 
      were performed to evaluate the prognosis of HCC. RESULTS: The mTOR pathway was 
      more significantly altered in high-grade tumors, and tumors with poor prognostic 
      features. Especially, pAkt and cytoplasmic p27 expression showed the strongest 
      associations with pathological parameters of HCC. Statistical analysis showed 
      that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different 
      overall survival rates relative to those not expressing these proteins. Cox 
      multi-factor analysis showed that tumor differentiation (P = 0.006), vascular 
      invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), 
      p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC. 
      CONCLUSION: Expression of the mTOR pathway components, which are related with the 
      transferability and invasive capacity of HCC cells, may be used as prognostic 
      indicators in HCC.
FAU - Zhou, Ledu
AU  - Zhou L
AD  - General Surgery Department of XiangYa Hosptial, Central South University, 
      Changsha, Hunan 410078, China.
FAU - Huang, Yun
AU  - Huang Y
FAU - Li, Jingdong
AU  - Li J
FAU - Wang, Zhiming
AU  - Wang Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20090320
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/biosynthesis/genetics/*physiology
MH  - Carcinoma, Hepatocellular/*diagnosis/*enzymology/mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver Neoplasms/*diagnosis/*enzymology/mortality
MH  - Male
MH  - Middle Aged
MH  - PTEN Phosphohydrolase/biosynthesis/genetics
MH  - Phosphatidylinositol 3-Kinase/biosynthesis/genetics
MH  - Prognosis
MH  - Signal Transduction/genetics/*physiology
MH  - Survival Rate/trends
MH  - TOR Serine-Threonine Kinases/biosynthesis/genetics/*physiology
MH  - Up-Regulation/genetics
EDAT- 2009/03/21 09:00
MHDA- 2011/01/13 06:00
CRDT- 2009/03/21 09:00
PHST- 2009/02/17 00:00 [received]
PHST- 2009/03/06 00:00 [accepted]
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2011/01/13 06:00 [medline]
AID - 10.1007/s12032-009-9201-4 [doi]
PST - ppublish
SO  - Med Oncol. 2010 Jun;27(2):255-61. doi: 10.1007/s12032-009-9201-4. Epub 2009 Mar 
      20.